Back to Search Start Over

Cerebrospinal Fluid C18 Ceramide Associates with Markers of Alzheimer's Disease and Inflammation at the Pre- and Early Stages of Dementia.

Authors :
Teitsdottir, Unnur D.
Halldorsson, Skarphedinn
Rolfsson, Ottar
Lund, Sigrun H.
Jonsdottir, Maria K.
Snaedal, Jon
Petersen, Petur H.
Source :
Journal of Alzheimer's Disease; 2021, Vol. 81 Issue 1, p231-244, 14p
Publication Year :
2021

Abstract

<bold>Background: </bold>Understanding how dysregulation in lipid metabolism relates to the severity of Alzheimer's disease (AD) pathology might be critical in developing effective treatments.<bold>Objective: </bold>To identify lipid species in cerebrospinal fluid (CSF) associated with signature AD pathology and to explore their relationships with measures reflecting AD-related processes (neurodegeneration, inflammation, deficits in verbal episodic memory) among subjects at the pre- and early symptomatic stages of dementia.<bold>Methods: </bold>A total of 60 subjects that had been referred to an Icelandic memory clinic cohort were classified as having CSF AD (n = 34) or non-AD (n = 26) pathology profiles. Untargeted CSF lipidomic analysis was performed using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS) for the detection of mass-to-charge ratio (m/z) features. CSF proteins reflecting neurodegeneration (neurofilament light [NFL]) and inflammation (chitinase-3-like protein 1 [YKL-40], S100 calcium-binding protein B [S100B], glial fibrillary acidic protein [GFAP]) were also measured. Rey Auditory Verbal Learning (RAVLT) and Story tests were used for the assessment of verbal episodic memory.<bold>Results: </bold>Eight out of 1008 features were identified as best distinguishing between the CSF profile groups. Of those, only the annotation of the m/z feature assigned to lipid species C18 ceramide was confirmed with a high confidence. Multiple regression analyses, adjusted for age, gender, and education, demonstrated significant associations of CSF core AD markers (Aβ42: st.β= -0.36, p = 0.007; T-tau: st.β= 0.41, p = 0.005) and inflammatory marker S100B (st.β= 0.51, p = 0.001) with C18 ceramide levels.<bold>Conclusion: </bold>Higher levels of C18 ceramide associated with increased AD pathology and inflammation, suggesting its potential value as a therapeutic target. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
13872877
Volume :
81
Issue :
1
Database :
Complementary Index
Journal :
Journal of Alzheimer's Disease
Publication Type :
Academic Journal
Accession number :
151821023
Full Text :
https://doi.org/10.3233/JAD-200964